Does Medicaid Cover GLP-1 Drugs Like Ozempic and Wegovy? Here’s What Varies by State

Medicaid coverage for GLP-1 drugs depends heavily on where you live. That’s the frustrating truth many beneficiaries discover once they start asking questions about Ozempic, Wegovy, Mounjaro, or Zepbound.

These medications first earned FDA approval for type 2 diabetes. Semaglutide goes by the brand names Ozempic and Wegovy. Tirzepatide appears as Mounjaro and Zepbound. Both drugs act on gut hormones that boost insulin production, slow digestion, and increase feelings of fullness. That mechanism also explains why doctors now prescribe them so often for weight loss. However, popularity doesn’t guarantee coverage, especially through Medicaid.

For diabetes treatment, the picture looks fairly consistent. Most state Medicaid programs cover GLP-1 drugs since they carry direct FDA approval for type 2 diabetes. Still, a diagnosis alone won’t unlock coverage automatically.

Patients typically need lab results showing elevated HbA1c levels, the marker doctors use to track blood sugar over time. Many states also require proof of step therapy first. In other words, you likely need to try cheaper generics like metformin before your plan approves a GLP-1. On top of that, most plans require prior authorization, so your doctor must submit supporting documentation before coverage kicks in.

Weight loss coverage tells a very different story. Medicaid treats obesity coverage as optional rather than mandatory. Because of that, each state decides independently whether to cover GLP-1s for weight management. As of July 2026, only eleven states have opted in: Minnesota, Michigan, Wisconsin, Delaware, Virginia, North Carolina, Mississippi, Tennessee, Missouri, Kansas, and Utah.

Even among these states, rules differ significantly. Some cover only certain brands. Others set BMI requirements well above federal guidelines.

Federal standards generally call for a BMI of 30 or higher, or 27 with a related condition like heart disease or sleep apnea. Yet states can raise that threshold at will. Michigan, for instance, requires a BMI of 40, far above the federal baseline.

Most states also want documented proof of prior weight loss attempts. That usually means showing you tried diet changes, exercise, or a medication like phentermine before your plan approves a GLP-1 for weight loss.

A major policy shift could soon reshape this entire landscape. The Centers for Medicare and Medicaid Services recently launched the BALANCE model, short for Better Approaches to Lifestyle and Nutrition for Comprehensive Health. Through this program, state Medicaid agencies can negotiate lower, standardized GLP-1 prices while pairing coverage with lifestyle support services, directly addressing the ongoing debate over drug cost.

States may apply voluntarily between May 2026 and January 1, 2027. Participation, though, remains entirely optional. Nothing in the model requires states to join.

That uncertainty already shows up in real policy decisions. Some states that once covered GLP-1s for obesity have scaled back due to budget pressure. Others continue debating whether to expand access, tighten restrictions, or negotiate better pricing deals.

In short, GLP-1 coverage under Medicaid remains a moving target rather than a fixed benefit.

So how do you find out where you stand? Start by checking your state’s Medicaid preferred drug list or formulary. Search for your exact medication and confirm it’s covered for your specific diagnosis, not just approved in general terms.

Next, call the number listed on your Medicaid or pharmacy benefit card. Plan representatives can walk you through exactly what’s covered, what it might cost out of pocket, and what paperwork you’ll need.

Your prescriber’s office can also help significantly. Most offices understand the prior authorization process well and can submit the right documentation on your behalf.

Ultimately, Medicaid coverage for GLP-1 medications varies by diagnosis, by state, and sometimes even by brand. Given how quickly policy continues shifting, particularly with the BALANCE model rollout underway, checking your coverage regularly makes far more sense than assuming last year’s rules still apply.